All companies
Vertex Pharmaceuticals logo
HealthcareVRTX

Vertex Pharmaceuticals (VRTX) Financial Forecast Calculator

Interactive 5-year forecast and DCF for Vertex Pharmaceuticals. Adjust revenue growth, gross margin, capex intensity, WACC, and terminal growth - see revenue, free cash flow, and enterprise value update in real time. Seeded from Vertex Pharmaceuticals’s most recent SEC filings.

Revenue FY30
$24.56B
from $9.87B
FCF FY30
$5.59B
Margin 22.8%
Enterprise value
$72.47B
7.3× LTM revenue
Equity value
$82.97B
Net debt -$10.50B
Revenue & free cash flow - history and 5-year forecast
Line (area)
Bars
Historicals from SEC EDGAR (grey). Forecast years (color) update live as you move the sliders.

Assumptions

Revenue growth (annual)
20.0%
-10.0%baseline 20.0%40.0%
Gross margin
87.6%
5.0%baseline 87.6%90.0%
Capex % of revenue
2.7%
0.0%baseline 2.7%30.0%
WACC (discount rate)
9.00%
4.0%baseline 9.0%18.0%
Terminal growth
2.50%
0.0%baseline 2.5%5.0%

Need this as an Excel model?

Keep iterating on the Vertex Pharmaceuticals forecast in Excel. The downloadable sample has every assumption you see here plus a fully integrated income statement, balance sheet, cash flow, and debt schedule - five years of SEC historicals and live formulas in a fully editable workbook.

income_statement.xlsx
Income statement, brown brand palette
income_statement.xlsx
Income statement, green brand palette
income_statement.xlsx
Income statement, red brand palette

Frequently asked

What does Vertex Pharmaceuticals do?+

Vertex Pharmaceuticals is a global biotechnology company focused on discovering, developing, and commercializing transformative medicines for people with serious diseases. It established its foundation by treating the underlying cause of cystic fibrosis and is now diversifying into gene therapy, non-opioid pain management, and autoimmune diseases.

What are the primary revenue drivers for Vertex Pharmaceuticals?+

Vertex Pharmaceuticals' revenue is predominantly driven by its Cystic Fibrosis franchise, which accounted for approximately 99% of its 2024 revenue. Future growth is anticipated from new product launches such as the gene therapy Casgevy and the acute pain medication Journavx.

How does the Vertex Pharmaceuticals financial model account for new product launches?+

The Vertex Pharmaceuticals financial model is designed to forecast the cash flow durability of the cystic fibrosis franchise while probability-weighting the commercial ramp of recent and upcoming launches. This includes products like Casgevy, Journavx, and povetacicept, enabling comprehensive equity valuation and pipeline scenario planning.

What is Vertex Pharmaceuticals' capital expenditure strategy?+

Vertex Pharmaceuticals' capital expenditure typically ranges from 2% to 3% of revenue, primarily consisting of growth capex. This investment supports the expansion of R&D laboratory footprints and the buildout of internal cell and genetic therapy manufacturing capabilities in the Boston area.

Can I download an Excel financial model for Vertex Pharmaceuticals?+

Yes, a comprehensive Excel financial model for Vertex Pharmaceuticals is available for download. This general corporate model provides an equity valuation and pipeline scenario planning tool with a forecast horizon from FY2026 to FY2030.

How much does Vertex Pharmaceuticals invest in research and development?+

Vertex Pharmaceuticals operates with an asset-light manufacturing model but makes significant investments in intellectual property and R&D. The financial model assumes R&D expenses at approximately 35% of revenue, reflecting its commitment to discovering and developing new medicines.

Have more financial modelling questions? Contact us

Go further

Build the financial model you need with Fina

Browse templates, examples, and downloadable Excel models for the analysis you are trying to build. If you can't find your model, ask Fina to build a model for your specific needs.

Start for free
Excel financial model spreadsheet preview showing Customer Rollforward
Fina interactive chat interface preview